A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)

Trial Profile

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 498
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 03 May 2016 Planned number of patients changed from 640 to 1200.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top